drugset / Trial / NCT00621673
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
Non-randomizedSingle-groupOpen-labelSupportive care
Summary
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study is to further monitor whether participants with severe Hemophilia A will develop inhibitors or antibodies at the later stage when switched from their current recombinant therapy produced from Chinese Hamster Ovary (CHO) cell line to Kogenate-FS raised in a Baby Hamster Kidney cell line.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADVATE | Protein / enzyme biologic | 20 iu/kg | — |
| Subject | ADVATE | Protein / enzyme biologic | 40 iu/kg | — |